Search
Saxagliptin
go.drugbank.com/drugs/DB06335ApprovedInvestigationalSaxagliptin (rINN) is an orally active hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. FDA approved on July 31, 2009.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesIsavuconazonium
go.drugbank.com/drugs/DB06636ApprovedInvestigationalIsavuconazonium is a second-generation triazole antifungal approved on March 6, 2015 by the FDA and July 2015 by the EMA for the treatment of adults with invasive aspergillosis and invasive mucormycosis, marketed by Astellas under the br...
Categories: P-glycoprotein inhibitors, Cytochrome P-450 CYP2B6 InducersDesvenlafaxine
go.drugbank.com/drugs/DB06700ApprovedInvestigationalDesvenlafaxine (O-desmethylvenlafaxine) is the 0-demetyhlated active metabolite of venlafaxine. Like its parent drug, desvenlafaxine is also an antidepressant belonging to the class of serotonin-norepinephrine reuptake inhibitor (SNRI) c...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InhibitorsFosaprepitant
go.drugbank.com/drugs/DB06717ApprovedInvestigationalFosaprepitant is an intravenously administered antiemetic drug. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment.
Categories: Cytochrome P-450 CYP2C9 Inducers, Cytochrome P-450 SubstratesPhenylbutyric acid
go.drugbank.com/drugs/DB06819ApprovedInvestigationalPhenylbutyric acid is a fatty acid and a derivative of butyric acid naturally produced by colonic bacteria fermentation. It demonstrates a number of cellular and biological effects, such as relieving inflammation and acting as a chemical...
Categories: Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 Enzyme InhibitorsPitavastatin
go.drugbank.com/drugs/DB08860ApprovedInvestigationalPitavastatin, also known as the brand name product Livalo, is a lipid-lowering drug belonging to the statin class of medications. By inhibiting the endogenous production of cholesterol within the liver, statins lower abnormal cholesterol...
Categories: Cytochrome P-450 Substrates, P-glycoprotein substratesRegorafenib
go.drugbank.com/drugs/DB08896ApprovedInvestigationalRegorafenib is an orally-administered inhibitor of multiple kinases. It is used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and hepatocellular carcinoma. FDA approved on September 27, 201...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesBedaquiline
go.drugbank.com/drugs/DB08903ApprovedInvestigationalBedaquiline is a bactericidal antimycobacterial drug belonging to the class of diarylquinoline. The quinolinic central heterocyclic nucleus with alcohol and amine side chains is responsible for bedaquiline-mediated antimycobacterial acti...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesDabrafenib
go.drugbank.com/drugs/DB08912ApprovedInvestigationalDabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic n...
Categories: P-glycoprotein substrates, Cytochrome P-450 CYP2B6 InducersAfatinib
go.drugbank.com/drugs/DB08916ApprovedInvestigationalAfatinib is a 4-anilinoquinazoline tyrosine kinase inhibitor in the form of a dimaleate salt available as Boehringer Ingelheim's brand name Gilotrif [FDA Label]. For oral use, afatinib tablets are a first-line (initial) treatment for pat...
Categories: P-glycoprotein inhibitors, P-glycoprotein substrates